Retreatment With Radium-223 Safe, Showing Activity in Patients With CRPC and Bone Metastases

Slideset - Results from this small exploratory study suggest that radium-223 retreatment is well tolerated and may help delay future bone events in patients with CRPC and bone metastases who experience radiographic or clinical progression following an initial course of radium-223.
Source: Clinical Care Options Prostate Cancer - Category: Cancer & Oncology Source Type: research